BioImage Licenses Assay Tech to Merck; Signs Drug-Profiling Deal With Organon | GenomeWeb

For a company whose original aim was internal drug discovery, BioImage sure has the makings of a major tools provider for drug screening — a posture solidified by two major deals inked last week.

BioImage, headquartered in Denmark, announced on Sept. 7 that it had signed a research agreement with drug maker Organon, in which BioImage will profile certain Organon compounds at its Copenhagen research facility using a series of its Redistribution fluorescence cell-based assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.